W. Goettsch, PhD

Netherlands Healthcare Institute (ZINL), EUnetHTA

Speaker Module D

Wim Goettsch is currently the Project Leader of work package 5 of the European Network of HTA (EUnetHTA) Joint Action 2 (2012-2015) in which rapid joint assessments of relative effectiveness of pharmaceuticals are piloted between more than 25 HTA organisations around Europe. Until the beginning of 2013, Dr. Goettsch was the Deputy Secretary of the Medicinal Products Reimbursement Committee at Dutch National Health Care Institute (formerly known as CVZ). Currently, he is also Advisor of International Affairs and Academia for the National Health Care Institute and involved in projects around Medicines Adaptive Pathways to Patients (MAPPs) and real world data (IMI-GetReal project). He also works as a visiting scientist for the Department of Pharmacoepidemiology and Pharmacotherapy at the University of Utrecht and has been (2013-2015) Director in the Board of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR). 

Dr. Goettsch has an MSc in environmental toxicology, a PhD in immunology and an advanced education in (pharmaco)- epidemiology and pharmaco-economics. Before joining the National Health Care Institute, he worked as a research manager for the PHARMO Institute and was responsible for coordination of numerous pharmacoepidemiological and outcomes studies for international offices of pharmaceutical companies such as AstraZeneca, Novartis, Pfizer and GSK. Dr. Goettsch has more than 50 publications in peer-reviewed international journals. He also worked as a senior epidemiologist in the field of antimicrobial resistance for the National Institute for Public Health and the Environment in the Netherlands and was involved in the initiation of the European Antimicrobial Resistance Surveillance Network (EARS-Net) that is now coordinated by the ECDC.